Ceruloplasmin and superoxide dismutase (SOD1) in Parkinson's disease: a follow-up study

2.50
Hdl Handle:
http://hdl.handle.net/2336/54094
Title:
Ceruloplasmin and superoxide dismutase (SOD1) in Parkinson's disease: a follow-up study
Authors:
Torsdottir, Gudlaug; Sveinbjornsdottir, Sigurlaug; Kristinsson, Jakob; Snaedal, Jon; Johannesson, Torkell
Citation:
J. Neurol. Sci. 2006, 241(1-2):53-8
Issue Date:
15-Feb-2006
Abstract:
In this follow-up study concentration, oxidative activity and specific oxidative activity of ceruloplasmin (CP) in serum and the activity of superoxide dismutase (SOD1) in erythrocytes were reexamined in 28 of originally 40 patients with Parkinson's disease (PD), and their age- and gender-matched controls. The mean CP and SOD1 parameters were significantly lower in the patients than in the controls. SOD1 activity and age of the patients were inversely correlated. The patients were divided into two subgroups based on their H&Y score i.e. groups II and III (12 patients) versus groups IV and V (16 patients). No significant difference was found in the CP or SOD1 parameters between the subgroups. Patients were also divided into two subgroups based on treatment with levodopa and decarboxylase blocker alone (12 patients) or given additionally a dopamine agonist (15 patients). No significant difference in the parameters was found between these subgroups in relation to intake of dopamine agonists. Results of this study are in agreement with results of the former study 5 years earlier. There is considerable overlap in individual values between patients and controls of the parameters studied. Thus CP and SOD1 have no obvious value for diagnosis or clinical evaluation of PD.
Description:
To access publisher full text version of this article. Please click on the hyperlink in Additional Links field
Additional Links:
http://www.sciencedirect.com/science/article/B6T06-4HSXW5C-1/2/f22d5c70e561928cef9e96acc39a5185

Full metadata record

DC FieldValue Language
dc.contributor.authorTorsdottir, Gudlaug-
dc.contributor.authorSveinbjornsdottir, Sigurlaug-
dc.contributor.authorKristinsson, Jakob-
dc.contributor.authorSnaedal, Jon-
dc.contributor.authorJohannesson, Torkell-
dc.date.accessioned2009-03-11T09:50:41Z-
dc.date.available2009-03-11T09:50:41Z-
dc.date.issued2006-02-15-
dc.date.submitted2009-03-11-
dc.identifier.citationJ. Neurol. Sci. 2006, 241(1-2):53-8en
dc.identifier.issn0022-510X-
dc.identifier.pmid16352311-
dc.identifier.doi10.1016/j.jns.2005.10.015-
dc.identifier.urihttp://hdl.handle.net/2336/54094-
dc.descriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links fielden
dc.description.abstractIn this follow-up study concentration, oxidative activity and specific oxidative activity of ceruloplasmin (CP) in serum and the activity of superoxide dismutase (SOD1) in erythrocytes were reexamined in 28 of originally 40 patients with Parkinson's disease (PD), and their age- and gender-matched controls. The mean CP and SOD1 parameters were significantly lower in the patients than in the controls. SOD1 activity and age of the patients were inversely correlated. The patients were divided into two subgroups based on their H&Y score i.e. groups II and III (12 patients) versus groups IV and V (16 patients). No significant difference was found in the CP or SOD1 parameters between the subgroups. Patients were also divided into two subgroups based on treatment with levodopa and decarboxylase blocker alone (12 patients) or given additionally a dopamine agonist (15 patients). No significant difference in the parameters was found between these subgroups in relation to intake of dopamine agonists. Results of this study are in agreement with results of the former study 5 years earlier. There is considerable overlap in individual values between patients and controls of the parameters studied. Thus CP and SOD1 have no obvious value for diagnosis or clinical evaluation of PD.en
dc.language.isoenen
dc.publisherElsevieren
dc.relation.urlhttp://www.sciencedirect.com/science/article/B6T06-4HSXW5C-1/2/f22d5c70e561928cef9e96acc39a5185en
dc.subject.meshAgeden
dc.subject.meshAged, 80 and overen
dc.subject.meshCase-Control Studiesen
dc.subject.meshCeruloplasminen
dc.subject.meshErythrocytesen
dc.subject.meshFemaleen
dc.subject.meshFollow-Up Studiesen
dc.subject.meshHumansen
dc.subject.meshMaleen
dc.subject.meshMiddle Ageden
dc.subject.meshParkinson Diseaseen
dc.subject.meshSerumen
dc.subject.meshSuperoxide Dismutaseen
dc.titleCeruloplasmin and superoxide dismutase (SOD1) in Parkinson's disease: a follow-up studyen
dc.typeArticleen
dc.contributor.departmentInstitute of Pharmacy, Pharmacology and Toxicology, Department of Pharmacology and Toxicology, University of Iceland, Hofsvallagata 53, 107 Reykjavík, Iceland. gudlaugt@hi.isen
dc.identifier.journalJournal of the neurological sciencesen

Related articles on PubMed

All Items in Hirsla are protected by copyright, with all rights reserved, unless otherwise indicated.